Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

Ivan Spicka,Philippe Moreau,Thomas G. Martin,Thierry Facon,Gracia Martinez,Albert Oriol,Youngil Koh,Andrew Lim,Gábor Mikala,Laura Rosiñol,Münci Yağcı,Michele Cavo,Marie-Laure Risse,Gaëlle Asset,Sandrine Macé,Helgi van de Velde,Kwee Yong

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

2021

Ivan Spicka
Philippe Moreau
Thomas G. Martin
Thierry Facon
Gracia Martinez
Albert Oriol
Youngil Koh
Andrew Lim
Gábor Mikala
Laura Rosiñol
Münci Yağcı
Michele Cavo
Marie-Laure Risse
Gaëlle Asset
Sandrine Macé
Helgi van de Velde
Kwee Yong

8042Background: A prespecified interim efficacy analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d) (Isa-Kd) significantly i...

Keywords:

Isatuximab
Dexamethasone
Internal medicine
Subgroup analysis
Oncology
Cytogenetics
Medicine
Carfilzomib
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations